승모판 질환 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2030년)
Mitral Valve Disease Market - Global Mitral Valve Disease Industry Analysis, Size, Share, Growth, Trends and Forecast 2023-2030 -
상품코드:1490839
리서치사:Fairfield Market Research
발행일:2024년 05월
페이지 정보:영문 193 Pages
라이선스 & 가격 (부가세 별도)
한글목차
승모판 질환 시장 규모는 현재의 28억 달러에서 2030년까지 51억 2,000만 달러로 급증할 것으로 보이고 있습니다. 시장 매출은 2023-2030년 CAGR 9%의 고성장이 예측됩니다.
승모판 질환 시장은 선천적 이상과 감염으로 인한 승모판 질환의 유병률 증가로 인해 크게 확대되고 있습니다. 선천적 문제는 승모판막의 구조를 변화시켜 협착 및 역류와 같은 상태를 유발할 수 있습니다. 전 세계 인구의 고령화도 승모판 질환의 유병률 증가에 중요한 역할을 하고 있으며, 이로 인해 새로운 치료법에 대한 수요가 증가하고 있습니다. 승모판막 심장판막 및 관련 약물의 개발 및 승인에 대한 엄격한 규제에도 불구하고 의료 기술의 발전은 승모판 질환의 관리를 계속 강화하고 있습니다.
승모판 질환은 가장 흔한 심장 판막 질환 중 하나이며, 전 세계에서 수백만 명이 앓고 있습니다. 세계보건기구(WHO)에 따르면 전 세계에서 약 2,600만 명이 승모판 질환을 앓고 있습니다. 이 질환의 유병률은 연령에 따라 증가하며, 세계 인구의 고령화에 따라 효과적인 치료법에 대한 수요가 증가하고 있습니다. 또한 당뇨병과 비만과 같은 위험 요인은 승모판막 기능 부전의 발생률을 증가시켜 시장을 더욱 견인하고 있습니다.
세계의 승모판 질환 시장에 대해 조사했으며, 시장의 개요와 치료 유형별, 적응증별, 병기별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 경쟁 동향 등을 제공하고 있습니다.
목차
제1장 주요 요약
제2장 시장 개요
시장의 정의와 세분화
시장 역학
질병 역학
규제 시나리오
기술의 진보
질환 진단 상황
시술 건수
밸류체인 분석
Porter's Five Forces 분석
COVID-19의 영향 분석
우크라이나·러시아 분쟁의 영향
경제 개요
PESTLE 분석
제3장 세계의 승모판 질환 시장 전망, 2018-2030년
세계의 승모판 질환 시장 전망, 치료 유형별, 금액(10억 달러), 2018-2030년
세계의 승모판 질환 시장 전망, 적응증별, 금액(10억 달러), 2018-2030년
세계의 승모판 질환 시장 전망, 병기별, 금액(10억 달러), 2018-2030년
세계의 승모판 질환 시장 전망, 최종사용자별, 금액(10억 달러), 2018-2030년
세계의 승모판 질환 시장 전망, 지역별, 금액(10억 달러), 2018-2030년
제4장 북미의 승모판 질환 시장 전망, 2018-2030년
제5장 유럽의 승모판 질환 시장 전망, 2018-2030년
제6장 아시아태평양의 승모판 질환 시장 전망, 2018-2030년
제7장 라틴아메리카 승모판 질환 시장 전망, 2018-2030년
제8장 중동 및 아프리카의 승모판 질환 시장 전망, 2018-2030년
제9장 경쟁 구도
치료 유형과 적응증 히트맵
기업 시장 점유율 분석, 2022년
경쟁 대시보드
기업 개요
Abbott Laboratories
Medtronic plc
Edwards Lifesciences Corporation
Boston Scientific Corporation
LivaNova PLC
Micro Interventional Devices Inc.
XELTIS AG
Lepu Medical Technology(Beijing) Co. Ltd.
CryoLife Inc.
Colibri Heart Valve LLC
Valcare Medical
Affluent Medical
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Bayer AG
제10장 부록
KSA
영문 목차
영문목차
Market Overview
Mitral valve disease market size is set to surge from its current valuation of US$2.8 Bn to US$5.12 Bn by 2030. The market revenue is projected to experience a strong CAGR of 9% between 2023 and 2030.
The mitral valve disease market is experiencing significant expansion, driven by the increasing prevalence of mitral valve issues due to congenital abnormalities and infections. Congenital problems can alter the structure of the mitral valve, leading to conditions such as stenosis or regurgitation. The ageing global population also plays a critical role in the rising prevalence of mitral valve disease, thereby increasing the demand for new treatments. Despite stringent regulatory controls on the development and approval of mitral heart valves and related drugs, advancements in medical technology continue to enhance the management of mitral valve diseases.
Key Market Drivers
1. Growing Prevalence of Mitral Valve Disease: Mitral valve disease is among the most common heart valve conditions, affecting millions worldwide. According to the World Health Organization (WHO), approximately 26 million people globally suffer from mitral valve disease. The prevalence of this condition increases with age, and as the global population continues to age, the demand for effective treatments rises. Additionally, risk factors like diabetes and obesity further drive the market by increasing the incidence of mitral valve dysfunction.
2. Advancements in Technology: Innovations in medical technology and new treatment approaches have significantly improved the management of mitral valve disorders. Devices like the MitraClip, which offer a minimally invasive option for mitral valve repair, reduce mitral regurgitation and alleviate symptoms for patients who are not candidates for traditional surgery. Such technological advancements are driving the adoption of advanced treatments in the mitral valve disease market.
3. Increasing Adoption of Minimally Invasive Techniques: The demand for minimally invasive techniques for treating mitral valve disorders is growing. The development of devices like the Intrepid transcatheter mitral valve replacement (TMVR) system, which utilizes a minimally invasive transfemoral access approach, exemplifies this trend. These innovations are expected to propel market growth as they provide effective alternatives to traditional surgical procedures.
Market Challenges
1. High Costs Associated with Mitral Valve Replacement: The high cost of mitral valve replacement and repair surgeries poses a significant barrier to market growth. The cost of these procedures can vary based on factors such as disease severity, the type of procedure, and the healthcare facility. The financial burden associated with these surgeries can limit their accessibility, especially in lower-income regions.
2. Potentially Unfavorable Health Consequences: Regulatory restrictions imposed by governing bodies on the use, approval, and development of mitral heart valves and medications also hinder market growth. Strict guidelines must be followed during the production of mitral valve repair, replacement, and cardiac resynchronization devices to ensure their safety and quality. These regulations can slow down the development and commercialization of new treatments.
Emerging Trends and Opportunities
1. Growing Screening and Awareness Initiatives: Enhanced awareness campaigns, early diagnosis programs, and increased patient screening efforts are positively impacting the market. Early diagnosis by healthcare professionals improves the likelihood of successful treatments and enhances patient outcomes. Increased awareness leads to higher demand for advanced treatments, contributing to market growth.
2. Increasing Demand for Targeted Therapies and Personalized Medicine: Personalized medicine approaches, which tailor treatments based on individual patient characteristics and disease severity, have the potential to improve treatment outcomes and patient satisfaction. The integration of genetic testing and biomarker analysis into treatment decisions can optimize therapy approaches and drive market growth.
3. Expanding Presence of Key Companies: Collaborations between companies and healthcare organizations, along with exploring underserved regions for expansion, offer significant growth opportunities. Companies can increase market penetration by expanding product portfolios and distribution networks, creating a more competitive market landscape.
Regional Market Leaders
North America: North America is expected to hold the largest market share for mitral valve disease during the forecast period. The region's advanced healthcare system, increased consumer awareness, and high prevalence of mitral valve diseases contribute to this dominance. The rapid adoption of transcatheter mitral valve repair and replacement technology, along with significant improvements in minimally invasive procedures, is driving market growth in North America.
Asia-Pacific: The Asia-Pacific region is projected to experience the highest growth rate, driven by a large population base and rising purchasing power in countries like China and India. The booming pharmaceutical industry in these countries further supports this trend, making Asia-Pacific a key player in the global mitral valve disease market.
Europe: Europe also shows significant growth potential, driven by a well-established healthcare infrastructure and increased funding for the research and development of advanced treatments. European nations are focusing on developing cutting-edge medical technologies and personalized medical strategies, contributing to market growth.
In conclusion, the global mitral valve disease market is set for substantial growth, driven by the rising prevalence of mitral valve problems, technological advancements, and the increasing adoption of minimally invasive techniques. Addressing regulatory challenges and potential health risks will be crucial for sustaining growth and maximizing the market's potential.
Competitive Analysis
Abbott Laboratories
Medtronic plc
Edwards Lifesciences Corporation
Boston Scientific Corporation
LivaNova PLC
Micro Interventional Devices Inc.
XELTIS AG
Lepu Medical Technology (Beijing) Co. Ltd.
CryoLife Inc.
Colibri Heart Valve LLC
Valcare Medical
Affluent Medical
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Bayer AG
Global Mitral Valve Disease Treatment Market is Segmented as:
By Treatment Type
Mitral Valve Repair
Mitral Valve Replacement
Cardiac Resynchronization Therapy
Mitral Valve Therapeutics
Diuretics
Anticoagulants
Hypertension Drugs
By Indication
Mitral Valve Stenosis
Mitral Valve Prolapse
Mitral Valve Regurgitation
By Stage
Stage C
Stage D
By End User
Hospitals
Specialty Clinics
By Geographic Coverage:
North America
US
Canada
Europe
Germany
U.K.
France
Italy
Turkey
Russia
Rest of Europe
Asia Pacific
China
Japan
South Korea
India
Southeast Asia
Rest of Asia Pacific
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Middle East & Africa
GCC
South Africa
Egypt
Nigeria
Rest of Middle East & Africa
Table of Contents
1. Executive Summary
1.1. Global Mitral Valve Disease Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2022
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Disease Epidemiology
2.4. Regulatory Scenario
2.5. Technology Advancement
2.6. Disease Diagnostics Landscape
2.7. Number of procedures
2.7.1. Mitral Valve Repair
2.7.2. Mitral Valve Replacement
2.8. Value Chain Analysis
2.9. Porter's Five Forces Analysis
2.10. COVID-19 Impact Analysis
2.10.1. Supply
2.10.2. Demand
2.11. Impact of Ukraine-Russia Conflict
2.12. Economic Overview
2.12.1. World Economic Projections
2.13. PESTLE Analysis
3. Global Mitral Valve Disease Market Outlook, 2018 - 2030
3.1. Global Mitral Valve Disease Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2030
3.1.1. Key Highlights
3.1.1.1. Mitral Valve Repair
3.1.1.2. Mitral Valve Replacement
3.1.1.3. Cardiac Resynchronization Therapy
3.1.1.4. Mitral Valve Therapeutics
3.1.1.4.1. Diuretics
3.1.1.4.2. Anticoagulants
3.1.1.4.3. Hypertension Drugs
3.2. Global Mitral Valve Disease Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
3.2.1. Key Highlights
3.2.1.1. Mitral Valve Stenosis
3.2.1.2. Mitral Valve Prolapse
3.2.1.3. Mitral Valve Regurgitation
3.3. Global Mitral Valve Disease Market Outlook, by Stage, Value (US$ Bn), 2018 - 2030
3.3.1. Key Highlights
3.3.1.1. Stage C
3.3.1.2. Stage D
3.4. Global Mitral Valve Disease Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
3.4.1. Key Highlights
3.4.1.1. Hospitals
3.4.1.2. Specialty Clinics
3.5. Global Mitral Valve Disease Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa
4. North America Mitral Valve Disease Market Outlook, 2018 - 2030
4.1. North America Mitral Valve Disease Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2030
4.1.1. Key Highlights
4.1.1.1. Mitral Valve Repair
4.1.1.2. Mitral Valve Replacement
4.1.1.3. Cardiac Resynchronization Therapy
4.1.1.4. Mitral Valve Therapeutics
4.1.1.4.1. Diuretics
4.1.1.4.2. Anticoagulants
4.1.1.4.3. Hypertension Drugs
4.2. North America Mitral Valve Disease Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
4.2.1. Key Highlights
4.2.1.1. Mitral Valve Stenosis
4.2.1.2. Mitral Valve Prolapse
4.2.1.3. Mitral Valve Regurgitation
4.3. North America Mitral Valve Disease Market Outlook, by Stage, Value (US$ Bn), 2018 - 2030
4.3.1. Key Highlights
4.3.1.1. Stage C
4.3.1.2. Stage D
4.4. North America Mitral Valve Disease Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
